Biogen Inc vs VICI Properties Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while VICI Properties Inc trades at $26 (market cap $28.61B). The key difference: Biogen Inc and VICI Properties Inc are close in size by market cap, and VICI Properties Inc pays a 6.93% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VICI | |
|---|---|---|
Market Cap | $30.13B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $33.78 |
52-Week Low | $128.93 | $25.94 |
Enterprise Value | $37.20B | $46.16B |
Dividend Yield | — | 6.93% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →